한글목차

심막염의 개요

심막염은 심장의 내막인 심막의 염증으로 인해 발생하며, 주로 바이러스, 루푸스와 같은 염증성 질환, 류마티스 관절염이 원인입니다. 심막염 치료에는 항염증제와 부신피질 스테로이드가 사용됩니다. 지속 기간에 따라 급성 심막염과 만성 심막염으로 나뉩니다. 심막염은 인플루엔자 감염에 의해 발생하기 때문에 코로나 환자들에게도 나타납니다.

National Center for Biotechnology Information에 따르면, 일반 인구의 급성 심막염 발병률은 연간 10만 명당 약 27.7명입니다. 그러나 심막염 감염에는 바이러스성, 세균성, 진균성 등 많은 원인이 있습니다. 증상은 크게 다르지 않습니다. 거의 모든 사람에게 흉통, 발한, 호흡곤란을 일으킵니다.

시장 역학: 시장 성장 촉진요인과 시장 성장 억제요인

바이러스 관련 심막염의 유병률 증가

심막염은 바이러스 감염을 동반하는 경우가 많기 때문에 바이러스 감염이 심막염의 주요 원인으로 꼽힙니다. 하버드 헬스(Harvard Health)에 따르면, 심막염의 첫 번째 유발 요인은 바이러스 감염이며, 바이러스 감염으로 인해 심장을 포함한 다양한 장기에 체액이 축적되기 때문이라고 합니다. 심막염의 원인은 바이러스, 세균, 자가면역질환 등 다양한 요인에 의해 영향을 받기 때문에 예방보다는 치료가 더 현실적입니다.

세계보건기구(WHO) 2022 이슈에 따르면 매년 계절성 독감과 관련된 호흡기 질환으로 인해 65만 명이 사망하는 것으로 추정됩니다. 독감은 감염이 심장으로 이동하여 심막에 염증을 일으켜 심막염을 유발합니다.

코로나19도 인플루엔자가 신체의 거의 모든 부위에 염증을 일으켜 염증을 유발하기 때문에 심막염 사례가 보고되고 있으며, 2022년 12월 현재 6,618,579명의 COVID로 인한 사망자가 보고되었으며, 대부분 심장에 염증을 일으켰습니다. 예를 들어, AHA 저널 2023호에 따르면 SARS-CoV-2는 심근염/심막염의 발생률을 COVID 이전 수준보다 15배 이상 증가시켰지만, 이 증상은 여전히 드문 증상입니다.

또한, 심장 질환의 유병률 증가, 기술 혁신의 발전, 더 나은 진단 및 치료의 발전은 향후 일정 기간 동안 시장을 주도하는 요인입니다.

심막 절제술의 부작용

심막절제술의 부작용으로는 과다 출혈, 심방 및 심실 부정맥, 심실벽 파열 등이 있습니다. 심낭 절제술을 받은 환자 중 일부에서 혈전과 감염이 발생하기도 합니다. 이러한 위험을 극복하는 것은 수술의 위험성을 감안할 때 어려운 일입니다. 따라서 대부분의 심막염은 항염증제를 사용하여 치료하고 있으며, 치료 가능한 부작용도 적습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 지역 분석
• 규제 분석
• DMI의 견해

제6장 COVID-19 분석

제7장 질환 유형별

• 급성 심막염
• 급성 심막염
• 만성 심막염
• 기타

제8장 치료 유형별

• 약제
  • 진통제
  • 아스피린
  • 이부프로펜
  • 항염증제
  • 코르히틴
  • 코르티코스테로이드
  • 기타
• 시술
  • 심낭천자
  • 심막 절제술
  • 기타

제9장 최종사용자별

• 병원 및 클리닉
• 심장 센터
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• M&A분석

제12장 기업 개요

• Teva Pharmaceuticals USA, Inc.
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Par Pharmaceutical
• Merck KGaA
• Cumberland Pharmaceuticals Inc.
• Johnson & Johnson Inc.
• Bayer AG
• Midas Pharma GmbH.
• Alchem International Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• Azure Pharmaceuticals

제13장 부록

영문목차

Overview

Pericarditis is caused by inflammation of the pericardium, the lining of the heart, mainly driven by viruses, inflammatory diseases like lupus, and rheumatoid arthritis. Anti-inflammatory agents and corticosteroids are used for the treatment of pericarditis. Based on its duration, it is of two types, acute and chronic pericarditis. It is also seen in COVID patients as it is caused by flu infection.

According to the National Center for Biotechnology Information, the incidence of acute pericarditis in the general population is approximately 27.7 cases per 100,000 individuals annually. However, pericarditis infection has many causes, such as viral, bacterial, fungal, etc. The symptoms don't vary much. It causes chest pain, sweating, and breathlessness in almost every individual.

Market Dynamics: Drivers & Restraints

Increasing prevalence of virus-associated pericarditis

Viral infections are a leading cause of pericarditis worldwide, as the condition frequently coexists with viral infections. According to Harvard Health, the initial trigger for pericarditis is viral infections, as they cause fluid accumulation in various organs, including the heart. Treatment is more feasible than prevention because the cause of the disease is dependent on many factors, such as viruses, bacteria, autoimmune disorders, etc.

According to the World Health Organisation 2022 issue, every year, an estimated 650,000 deaths are caused due to respiratory diseases linked to seasonal influenza alone. Influenza leads to pericarditis as the infection moves to the heart and causes inflammation in the pericardium.

COVID-19 also reported pericarditis cases as the flu spread to almost every part of the body and caused inflammation. As of December 2022, 6,618,579 COVID deaths have been reported, most of which had heart inflammation. For instance, according to the AHA journal 2023 issue, SARS-CoV-2 increased the incidence of myocarditis/pericarditis by at least 15× over pre-COVID levels, although the condition remains rare.

Furthermore, increased prevalence of heart diseases, increased innovations, and advancements in better diagnosis and treatment are the factors that drive the market in the forthcoming period.

Side effects of pericardiectomy

Side effects of Pericardiectomy include excessive bleeding, atrial and ventricular arrhythmia, and even ventricular wall rupture. Blood clots and infection are also observed in a few patients undergoing Pericardiectomy. Overcoming these risks is difficult as the procedures are risky to perform. Hence, most pericarditis cases are treated using anti-inflammatory drugs, which causes fewer side effects that are often treatable.

Segment Analysis

The global pericarditis market is segmented based on disease type, treatment type, end user and region.

The Anti inflammatory drugs segment accounted for approximately 45.8% of the market share

Anti-inflammatory drugs are the first-line treatment for pericarditis. Companies are currently working on the same with increased efficacy and safety. The United States Food and Drug Administration is supporting Cardiol Therapeutics Inc. in conducting two Phase II studies in rare heart diseases, recurrent pericarditis, and acute myocarditis, as no other drugs are currently discovered for rare heart diseases like pericarditis.

In November 2022, Cardiol Therapeutics Inc. declared positive results demonstrating the protective effects of CardiolRx. It significantly reduces pericardial effusion and thickening of the pericardium.

In January 2023, Cardiol Therapeutics Inc. declared that the first patient had been enrolled in the company-sponsored Phase II study evaluating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis.

Geographical Analysis

North America accounted for approximately 40.6% of the market share in 2022

North America is expected to hold the largest market share due to the incidence of pericarditis in patients who received vaccines developed by U.S. companies. Pericarditis causes heart failure that affects more than 64 million people globally, and associated healthcare costs exceed $30 billion annually in the U.S. alone. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.

More than 22 million doses of Moderna have been administered in Canada, where the incidence of myocarditis, pericarditis, or myopericarditis is two to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine than the Pfizer vaccine. Forty-one pericarditis cases were immediately observed after the Moderna vaccine in Canada.

COVID-19 Impact Analysis:

COVID-19 had a slight, moderate impact on the pericarditis market. The supply chains were interrupted during the peak period of the infection. Most of the diagnostic centers were shut down due to the implementation of lockdowns worldwide. This impacted the diagnosis and, thus, treatment procedures for cardiovascular diseases, including pericarditis.

Many of them were postponed and diagnosed at later stages as there are many types of pericarditis with different causes; the treatment options vary, with individuals requiring extensive testing that was shut down entirely during the 19 period. Hence, all the research focused on vaccines and covid drug development.

Competitive Landscape

The major global players in the pericarditis market include: Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Merck KGaA, Cumberland Pharmaceuticals Inc., Johnson & Johnson Inc., Bayer AG, Midas Pharma GmbH., Alchem International Pvt. Ltd., Takeda Pharmaceutical Company Limited, Azure Pharmaceuticals among others.

Key Developments

• Rabin Medical Center is conducting phase 4 clinical trials to compare the efficacy of NSAID therapy and Dexamethasone therapy in patients suffering from pericarditis. The study start date is February 14, 2020. The estimated completion date is December 2023.
• In March 2021, Kiniksa Pharmaceuticals, Ltd. Received the U.S. Food and Drug Administration (FDA) approval for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. It was commercially launched in August 2021.

Why Purchase the Report?

• To visualize the global pericarditis market segmentation based on disease type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pericarditis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pericarditis market report would provide approximately 63 tables, 65 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Driver
    • 4.1.1.1. Increasing prevalence of virus-associated pericarditis
    • 4.1.1.2.
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects of pericardiectomy
    • 4.1.2.2.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regional Analysis
• 5.5. Regulatory Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Disease Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 7.1.2. Market Attractiveness Index, By Disease Type
• 7.2. Acute Pericarditis*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Incessant Pericarditis
• 7.4. Chronic Pericarditis
• 7.5. Others

8. By Treatment Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.1.2. Market Attractiveness Index, By Treatment Type
• 8.2. Drug*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.2.1. Pain Relievers
    • 8.2.2.1.1.1. Aspirin
    • 8.2.2.1.1.2. Ibuprofen
    • 8.2.2.2. Anti-inflammatory drugs
    • 8.2.2.2.1.1. Colchicine
    • 8.2.2.2.1.2. Corticosteroids
    • 8.2.2.2.1.3. Others
• 8.3. Procedure
  • 8.3.1.1. Pericardiocentesis
  • 8.3.1.2. Pericardiectomy
  • 8.3.1.3. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals and Clinics*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cardiac Centers
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Teva Pharmaceuticals USA, Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Par Pharmaceutical
• 12.3. Merck KGaA
• 12.4. Cumberland Pharmaceuticals Inc.
• 12.5. Johnson & Johnson Inc.
• 12.6. Bayer AG
• 12.7. Midas Pharma GmbH.
• 12.8. Alchem International Pvt. Ltd.
• 12.9. Takeda Pharmaceutical Company Limited
• 12.10. Azure Pharmaceuticals

LIST NOT EXHAUSTIVE.

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us